Literature DB >> 8180034

Prolonged continuous infusion of low-dose rIL-2.

R A Janssen, J Buter, T H The, N H Mulder, L de Leij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8180034      PMCID： PMC1968897          DOI： 10.1038/bjc.1994.189

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  7 in total

1.  Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.

Authors:  I Yoshino; T Yano; M Murata; T Ishida; K Sugimachi; G Kimura; K Nomoto
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

2.  HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.

Authors:  R A Janssen; J Buter; E Straatsma; A A Heijn; D T Sleijfer; E G de Vries; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 3.  An explanation of the variable clinical response to interleukin 2 and LAK cells.

Authors:  G Parmiani
Journal:  Immunol Today       Date:  1990-04

Review 4.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 5.  T cell recognition of human tumors: implications for molecular immunotherapy of cancer.

Authors:  C G Ioannides; T L Whiteside
Journal:  Clin Immunol Immunopathol       Date:  1993-02

6.  Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.

Authors:  G Weil-Hillman; K Schell; D M Segal; J A Hank; J A Sosman; P M Sondel
Journal:  J Immunother (1991)       Date:  1991-08

7.  A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

Authors:  L T Vlasveld; A Hekman; F A Vyth-Dreese; E M Rankin; J G Scharenberg; A C Voordouw; J J Sein; T A Dellemijn; S Rodenhuis; C J Melief
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.